Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 237.42M | 227.04M | 251.46M | 477.71M | 313.84M | 76.66M |
Gross Profit | 174.71M | 188.49M | 197.45M | 273.49M | 184.15M | 61.05M |
EBITDA | -384.69M | -484.39M | -821.29M | -2.06B | -1.81B | -108.58M |
Net Income | -472.07M | -547.03M | -892.87M | -2.10B | -1.83B | -126.61M |
Balance Sheet | ||||||
Total Assets | 1.29B | 1.38B | 1.67B | 2.54B | 2.07B | 675.15M |
Cash, Cash Equivalents and Short-Term Investments | 516.92M | 561.57M | 944.07M | 1.32B | 1.55B | 380.80M |
Total Debt | 434.56M | 467.73M | 241.77M | 442.59M | 23.03M | 17.00M |
Total Liabilities | 646.04M | 661.39M | 568.19M | 803.04M | 503.61M | 205.10M |
Stockholders Equity | 647.43M | 716.06M | 1.10B | 1.74B | 1.51B | 461.38M |
Cash Flow | ||||||
Free Cash Flow | -345.30M | -382.13M | -336.30M | -304.47M | -310.34M | -193.65M |
Operating Cash Flow | -281.85M | -319.58M | -295.50M | -252.20M | -253.82M | -135.83M |
Investing Cash Flow | -248.81M | -62.24M | -80.69M | -67.39M | -73.26M | -67.12M |
Financing Cash Flow | -1.10M | -1.74M | -3.22M | 95.34M | 1.53B | 90.32M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $510.67M | ― | ― | ― | ― | ||
54 Neutral | $741.01M | ― | -57.76% | ― | 13.76% | 48.34% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
45 Neutral | $406.65M | ― | -26.14% | ― | ― | 74.59% | |
44 Neutral | $430.67M | ― | -33.14% | ― | ― | ― | |
34 Underperform | $410.77M | ― | -45.82% | ― | ― | 10.38% | |
33 Underperform | $658.62M | ― | -71.44% | ― | ― | 19.94% |
On June 12, 2025, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, where a significant majority of shares were represented. The meeting resulted in the election of seven directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, shareholders approved the executive compensation on an advisory basis, indicating broad support for the company’s leadership and strategic direction.
The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.
On May 21, 2025, Ginkgo Bioworks announced the resignation of its Chief Financial Officer, Mark Dmytruk, effective May 30, 2025, as he transitions to another organization. Steven Coen, the current Chief Accounting Officer, will assume the role of CFO, bringing over 30 years of experience in public accounting and corporate finance. Coen’s appointment is expected to provide continuity and build upon the financial strategies laid out by Dmytruk, with a focus on achieving cost reduction targets and reaching Adjusted EBITDA breakeven by the end of 2026.
The most recent analyst rating on (DNA) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.